Epidemiology. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events
|
|
- Meghan Mason
- 5 years ago
- Views:
Transcription
1 Epidemiology Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Samia Mora, MD, MHS; Nader Rifai, PhD; Julie E. Buring, ScD; Paul M Ridker, MD, MPH Background Although guidelines recommend measuring fasting lipids for initial screening of adults without cardiovascular disease (CVD), recent studies suggest that nonfasting triglycerides may be superior to fasting. Whether fasting status alters associations of nontriglyceride lipids with CVD is unclear. Methods and Results In a prospective study of healthy women ( fasting; 6347 nonfasting), associations of baseline lipids with incident CVD (754 fasting; 207 nonfasting) were examined over an 11-year follow-up. Except for triglycerides, lipid concentrations differed minimally ( 5%) for fasting versus nonfasting. However, stronger associations with CVD were noted for fasting total cholesterol (adjusted fasting hazard ratio [HR], 1.22 per 1-SD increment; 95% CI, 1.14 to 1.30; nonfasting HR, 1.07; 95% CI, 0.93 to 1.21), low-density lipoprotein (LDL) cholesterol (fasting HR, 1.21; 95% CI, 1.13 to 1.29; nonfasting HR, 1.00; 95% CI, 0.87 to 1.15), apolipoprotein B-100 (fasting HR, 1.36; 95% CI, 1.27 to 1.45; nonfasting HR, 1.20; 95% CI, 1.05 to 1.36), non high-density lipoprotein (HDL) cholesterol (fasting HR, 1.29; 95% CI, 1.21 to 1.38; nonfasting HR, 1.15; 95% CI, 1.01 to 1.31), and apolipoprotein B-100/A-1 ratio (fasting HR, 1.39; 95% CI, 1.30 to 1.48; nonfasting HR, 1.18; 95% CI, 1.09 to 1.27). Compared with fasting levels, nonfasting HDL cholesterol, apolipoprotein A-1, and total/hdl cholesterol ratio had similar associations, and triglycerides had a stronger association, with CVD. Significant interactions were seen for LDL cholesterol and apolipoprotein B-100/A-1 ratio with fasting status (P for interaction 0.03 and 0.001, respectively). Conclusions This study demonstrates that HDL cholesterol, triglycerides, total/hdl cholesterol ratio, and apolipoprotein A-1 predict CVD when measured nonfasting. By contrast, total, LDL, and non-hdl cholesterol, in addition to apolipoprotein B-100 and B-100/A-1 ratio, provide less useful CVD risk information when nonfasting, despite small changes in their concentrations. Guidelines for lipid screening may need to consider these differences. (Circulation. 2008;118: ) Current guidelines recommend measurement of a fasting lipid profile for cardiovascular risk assessment. 1,2 Lipids are traditionally measured after an 8- to 12-hour fast to minimize the influence of postprandial lipemia. 3 Ingestion of a typical fat-containing meal results in higher triglyceride levels and smaller changes in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol. 4 The third report of the National Cholesterol Education Program Adult Treatment Panel (Adult Treatment Panel III) recommends that initial screening should include a fasting lipid profile that includes total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. 1 The guidelines allow for the measurement Key Words: apolipoproteins lipids women of total and HDL cholesterol in the nonfasting state 1 because levels of these 2 lipids are altered minimally when measured in fasting or nonfasting blood. 5,6 Non-HDL cholesterol, a secondary target of therapy in Adult Treatment Panel III, may also be used in the nonfasting state. 1 Editorial p Clinical Perspective p In apparent contrast to these guidelines, 3 studies have suggested that nonfasting triglycerides may better or similarly predict cardiovascular disease (CVD) events than fasting levels. 7 9 It has been increasingly recognized that postpran- Received March 4, 2008; accepted June 26, From the Donald W. Reynolds Center for Cardiovascular Research (S.M., J.E.B., P.M.R.), Leducq Center for Molecular and Genetic Epidemiology (S.M., P.M.R.), and Center for Cardiovascular Disease Prevention (S.M., P.M.R.), Division of Preventive Medicine (S.M., J.E.B., P.M.R.) and Division of Cardiovascular Medicine (S.M., P.M.R.), Brigham and Women s Hospital, Harvard Medical School, Boston, Mass; Department of Epidemiology, Harvard School of Public Health, Boston, Mass (J.E.B., P.M.R.); and Department of Laboratory Medicine, Children s Hospital and Harvard Medical School, Boston, Mass (N.R.). Guest Editor for this article is Judith S. Hochman, MD. Clinical trial registration information URL: Unique identifier: NCT Correspondence to Samia Mora, MD, MHS, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA smora@partners.org 2008 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA
2 2 Circulation September 2, 2008 Table 1. Baseline Characteristics of Participants According to Fasting Status* dial responses, such as those relating to glucose and triglyceride metabolism, may trigger a number of proatherosclerotic and prothrombotic processes, including inflammation, oxidative stress, and vasoconstriction. 10 It is unknown whether nonfasting status alters the association of nontriglyceride lipids and apolipoproteins with CVD. However, if postprandial effects do not substantially weaken the association of nontriglyceride lipids and apolipoproteins with CVD, then measurement of nonfasting lipids may have many practical advantages for clinical practice. Therefore, we conducted this study in a large prospective cohort of initially healthy women (1) to evaluate levels of lipids and apolipoproteins as a function of time after a typical meal and (2) to determine whether fasting compared with nonfasting status alters the association of these lipids and apolipoproteins with incident CVD. Methods Study Population Study participants were enrolled in the Women s Health Study, a recently completed randomized, double-blinded, placebo-controlled clinical trial of low-dose aspirin and vitamin E in the primary prevention of CVD and cancer in US female healthcare professionals Eligible participants were apparently healthy women, aged 45 years, who were free of self-reported CVD or cancer at study entry ( ), with follow-up for incident CVD through February At the time of enrollment, participants gave written informed consent and completed questionnaires on demographics, medical history, medications, and lifestyle factors. They were also asked to provide a blood sample. Participants were requested, but not required, to have the sample drawn in the morning before eating, and they reported the number of hours since their last meal before the Fasting (n ) Nonfasting (n 6347) Age, mean SD, y Current smoking, % Hypertension, % Diabetes, % Postmenopausal status, % Postmenopausal hormone use, % Body mass index, mean SD, kg/m Lipid concentrations, median (25th to 75th percentile), mg/dl Total cholesterol 209 ( ) 206 ( ) LDL cholesterol 123 ( ) 117 (97 140) HDL cholesterol 52 (43 62) 52 (43 62) 0.25 Triglycerides 115 (81 169) 133 (93 196) Apolipoprotein concentrations, median (25th to 75th percentile), mg/dl Apolipoprotein B (85 122) 98 (82 118) Apolipoprotein A ( ) 150 ( ) 0.68 Combined lipid measures, median (25th to 75th percentile) Non-HDL cholesterol, mg/dl 155 ( ) 152 ( ) Total/HDL cholesterol ratio 4.0 ( ) 3.9 ( ) 0.03 Apolipoprotein B-100/A-1 ratio 0.68 ( ) 0.66 ( ) P values were obtained from Student t tests for continuous variables expressed as means, from Kruskal-Wallis tests for variables expressed as medians, and from 2 tests for categorical variables. *Fasting defined as 8 hours since last meal. blood draw and the time of day for the blood draw. In total, women had baseline measurements on the lipids and apolipoproteins of interest. After exclusion of 1418 women because of missing data on the time since last meal, there were women for analysis. The study was approved by the institutional review boards of the Brigham and Women s Hospital (Boston, Mass). The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written. Baseline Plasma Measurements EDTA blood samples were obtained at the time of enrollment and stored in vapor phase liquid nitrogen ( 170 C). In a laboratory certified by the National Heart, Lung, and Blood Institute/Centers for Disease Control and Prevention Lipid Standardization program, baseline samples were thawed and analyzed for standard lipids and apolipoproteins. Total, LDL, and HDL cholesterol were assayed directly with reagents from Genzyme Corporation (Cambridge, Mass) and Roche Diagnostics (Indianapolis, Ind) with the use of a Hitachi 911 autoanalyzer. Apolipoproteins A-1 and B-100 were measured with immunoturbidimetric assays (DiaSorin, Stillwater, Minn). Definition of Fasting Status Participants whose last meal was 8 hours before their blood draw comprised the fasting sample (n ), and those who had eaten within 8 hours of their blood draw comprised the nonfasting sample (n 6347). The study population was also divided into groups according to time since last meal by 2-hour intervals of 2(n 991), 2to 4 (n 2782), 4 to 6 (n 1702), 6 to 8 (n 872), 8 to 10 (n 1321), 10 to 12 (n 3490), 12 to 14 (n 8550), 14 to 16 (n 5196), and 16 hours (n 1426). Ascertainment of CVD Events The primary end point of interest was a composite end point of incident CVD (nonfatal myocardial infarction, percutaneous coro- P
3 Mora et al Fasting vs Nonfasting Lipids and Incident CVD 3 Table 2. Associations of Lipids and Apolipoproteins With CVD According to Fasting Status Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for Trend Per 1 SD P P Interaction Lipid concentrations Total cholesterol Nonfasting ( ) 1.53 ( ) 1.10 ( ) 1.40 ( ) ( ) (n 6347) Fasting ( ) 1.62 ( ) 2.08 ( ) 2.28 ( ) ( ) (n ) LDL cholesterol Nonfasting ( ) 0.83 ( ) 0.93 ( ) 0.95 ( ) ( ) Fasting ( ) 1.44 ( ) 1.76 ( ) 1.83 ( ) ( ) HDL cholesterol Nonfasting ( ) 0.46 ( ) 0.33 ( ) 0.42 ( ) ( ) Fasting ( ) 0.74 ( ) 0.61 ( ) 0.49 ( ) ( ) Triglycerides Nonfasting ( ) 1.38 ( ) 1.96 ( ) 2.54 ( ) ( ) Fasting ( ) 2.27 ( ) 2.08 ( ) 2.63 ( ) ( ) Triglycerides* Nonfasting ( ) 1.26 ( ) 1.69 ( ) 2.04 ( ) ( ) Fasting ( ) 1.75 ( ) 1.42 ( ) 1.47 ( ) ( ) 0.09 Apolipoprotein concentrations Apolipoprotein B-100 Nonfasting ( ) 1.00 ( ) 1.08 ( ) 1.77 ( ) ( ) Fasting ( ) 1.54 ( ) 1.69 ( ) 2.61 ( ) ( ) Apolipoprotein A-1 Nonfasting ( ) 0.65 ( ) 0.49 ( ) 0.72 ( ) ( ) Fasting ( ) 0.67 ( ) 0.66 ( ) 0.58 ( ) ( ) Combined lipid measures Non-HDL cholesterol Nonfasting ( ) 0.95 ( ) 1.03 ( ) 1.49 ( ) ( ) Fasting ( ) 2.24 ( ) 2.22 ( ) 2.99 ( ) ( ) Total/HDL cholesterol ratio Nonfasting ( ) 0.90 ( ) 1.43 ( ) 2.36 ( ) ( ) Fasting ( ) 1.73 ( ) 1.94 ( ) 2.90 ( ) ( ) Apolipoprotein B-100/A-1 ratio Nonfasting ( ) 0.73 ( ) 1.05 ( ) 1.68 ( ) ( ) Fasting ( ) 1.96 ( ) 2.12 ( ) 3.29 ( ) ( ) Values shown are HRs (95% CIs) adjusted for age, randomized treatment assignment, smoking status, menopausal status, postmenopausal hormone use, blood pressure, diabetes, and body mass index. P value for linear trend was obtained with the median value for each quintile. P interaction was obtained from likelihood ratio tests for interaction with fasting/nonfasting status and the lipid variable in relation to CVD. *Additionally adjusted for total and HDL cholesterol. nary intervention, coronary artery bypass grafting, nonfatal stroke, or cardiovascular death). During the 11-year follow-up period, women reported the end points of interest on follow-up questionnaires every 6 or 12 months. All events were adjudicated by an end points committee. Statistical Analysis Statistical analyses were performed with the use of STATA version 8.2 (STATA Corporation, College Station, Tex). Statistical comparisons between the fasting and nonfasting groups were obtained from Student t tests for continuous variables expressed as means, from Kruskal-Wallis tests for variables expressed as medians, and from 2 tests for categorical variables. The levels of the lipids and apolipoproteins were examined as a function of time since the last meal divided into 2-hour intervals. Following guidelines from the Department of Health and Human Services, 14 lipid biomarkers were divided into quintiles on the basis of the distribution among women not taking hormone replacement. Because the distributions differed between fasting and nonfasting participants for some of the lipid measurements, quintile cut points were defined separately in each of the fasting and nonfasting samples. To address whether the results may differ on the basis of the cut points used, analyses were also performed per 1-SD increment in each lipid variable. The 1-SD increments were similar for fasting and nonfasting samples. To examine the predictive value of levels of lipids and apolipoproteins for CVD risk depending on the time since the last meal divided into 2-hour intervals, analyses were repeated per 1-SD increments within strata of time since last meal by 2-hour intervals. Cox proportional hazard regression models were used to calculate the hazard ratios (HRs) and 95% CIs according to these quintiles and per 1-SD increments.
4 4 Circulation September 2, 2008 Table 3. Associations of Lipids and Apolipoproteins With CVD, According to Fasting Status and Postmenopausal Hormone Use Non Hormone Users (n 3531 Nonfasting; n Fasting) Hormone Users (n 2801 Nonfasting; n 8688 Fasting) Per1SD P Per1SD P Lipid concentrations Total cholesterol Nonfasting 1.10 ( ) ( ) 0.81 Fasting 1.27 ( ) ( ) 0.02 LDL cholesterol Nonfasting 1.06 ( ) ( ) 0.37 Fasting 1.26 ( ) ( ) 0.03 HDL cholesterol Nonfasting 0.68 ( ) ( ) 0.12 Fasting 0.74 ( ) ( ) Triglycerides Nonfasting 1.22 ( ) ( ) Fasting 1.27 ( ) ( ) Triglycerides* Nonfasting 1.12 ( ) ( ) 0.01 Fasting 1.07 ( ) ( ) 0.38 Apolipoprotein concentrations Apolipoprotein B-100 Nonfasting 1.25 ( ) ( ) 0.24 Fasting 1.40 ( ) ( ) Apolipoprotein A-1 Nonfasting 0.80 ( ) ( ) 0.34 Fasting 0.74 ( ) ( ) 0.05 Combined lipid measures Non-HDL cholesterol Nonfasting 1.19 ( ) ( ) 0.41 Fasting 1.35 ( ) ( ) Total/HDL cholesterol ratio Nonfasting 1.34 ( ) ( ) 0.05 Fasting 1.42 ( ) ( ) Apolipoprotein B-100/A-1 ratio Nonfasting 1.18 ( ) ( ) 0.08 Fasting 1.42 ( ) ( ) Values shown are HRs (95% CIs) adjusted for age, randomized treatment assignment, smoking status, menopausal status, postmenopausal hormone use, blood pressure, diabetes, and body mass index. P value for linear trend was obtained with the median value for each quintile. *Additionally adjusted for total and HDL cholesterol. Likelihood ratio test for interaction with fasting/nonfasting status: LDL cholesterol for hormone users, P for interaction 0.06; apolipoprotein B-100/A-1 for non hormone users, P for interaction To examine the extent to which each lipid or lipoprotein biomarker was associated with incident events, we considered each lipid variable in a separate model that adjusted for nonlipid risk factors (age, randomized treatment assignment, smoking status, menopausal status, postmenopausal hormone use, blood pressure, diabetes, and body mass index). Analyses for triglycerides were additionally adjusted for total and HDL cholesterol based on prior work from this cohort. 8 To address any potential confounding from time of day for the blood draw, we additionally adjusted the multivariable models for time of blood draw, which did not affect the findings. P value for linear trend was obtained with the use of the median value for each quintile. All P values were 2-tailed. Finally, statistical tests for interaction between fasting status and each of the lipids or apolipoproteins in relation to incident CVD were obtained with the use of likelihood ratio tests.
5 Mora et al Fasting vs Nonfasting Lipids and Incident CVD 5 mg/dl mg/dl Total Cholesterol Non-HDL Cholesterol LDL Cholesterol < Time since last meal, hrs Apolipoprotein A-1 Apolipoprotein B100 < Time since last meal, hrs Results Table 1 shows the baseline characteristics of participants according to fasting or nonfasting status. Nonfasting women were slightly younger, had less prevalent hypertension, had more diabetes, and were less likely to be postmenopausal than fasting women. Compared with fasting lipids, nonfasting lipids were modestly (by 1% to 5%) but statistically significantly lower for total cholesterol, LDL cholesterol, apolipoprotein B-100, non-hdl cholesterol, total/hdl cholesterol ratio, and apolipoprotein B-100/A-1 ratio, with no significant difference for HDL cholesterol or apolipoprotein A-1. As anticipated, triglycerides were higher in the nonfasting women (by 15%). During a median follow-up of 11.4 years, a total of 961 first CVD events occurred (3.34 events per 1000 person-years of follow-up), which affected 754 of fasting women (3.8%) and 207 of 6347 nonfasting women (3.3%). Associations of each lipid variable with incident CVD were examined according to nonfasting or fasting quintiles and per 1-SD increments, in separate Cox regression models that considered each lipid variable, one at a time, and adjusted for nonlipid risk factors (Table 2). Nonfasting levels of total cholesterol and LDL cholesterol were not associated with CVD (adjusted nonfasting HR per 1-SD increment in total mg/dl Ratio Triglycerides HDL Cholesterol < Time since last meal, hrs Total / HDL Cholesterol Apolipoprotein B100 / A-1 < Time since last meal, hrs Figure 1. Median and 25th to 75th percentile values for lipids and apolipoproteins as a function of time since the last meal. cholesterol 1.07; 95% CI, 0.93 to 1.21; P 0.35; and for LDL cholesterol, 1.00; 95% CI, 0.87 to 1.15; P 1.0). By contrast, fasting levels of both total cholesterol and LDL cholesterol were significantly associated with CVD (fasting HRs, respectively, of 1.22 [95% CI, 1.14 to 1.30] and 1.21 [95% CI, 1.13 to 1.29]; P for both). Stronger associations with CVD were also noted for fasting compared with nonfasting levels of apolipoprotein B-100 (fasting HR, 1.36; 95% CI, 1.27 to 1.45; nonfasting HR, 1.20; 95% CI, 1.05 to 1.36), non-hdl cholesterol (fasting HR, 1.29; 95% CI, 1.21 to 1.38; nonfasting HR, 1.15; 95% CI, 1.01 to 1.31), and apolipoprotein B-100/A-1 ratio (fasting HR, 1.39; 95% CI, 1.30 to 1.48; nonfasting HR, 1.18; 95% CI, 1.09 to 1.27). Fasting and nonfasting associations of HDL cholesterol, apolipoprotein A-1, and total/hdl cholesterol ratio with CVD were comparable. A statistically significant interaction was seen between fasting/nonfasting status and LDL cholesterol for incident CVD (P for interaction 0.03) and for apolipoprotein B-100/A-1 ratio (P for interaction 0.001), with a borderline significant interaction between total cholesterol and CVD (P for interaction 0.10). Consistent with our prior report, 8 both fasting and nonfasting triglycerides were positively associated with CVD, but further adjustment for total cholesterol and HDL cholesterol weakened the association of fasting triglycerides with CVD.
6 6 Circulation September 2, 2008 Figure 2. HRs and 95% CIs (shown on a log-scale) for 1-SD increment of lipids and apolipoproteins, adjusted for age, randomized treatment assignment, smoking status, menopausal status, postmenopausal hormone use, blood pressure, diabetes, and body mass index. Including time of day for blood draw in the multivariable models did not change our findings. When we compared the association of fasting and nonfasting lipids and apolipoproteins in women grouped according to baseline use of postmenopausal hormones (Table 3), a similar pattern was observed. The associations of lipids and apolipoproteins with CVD were overall somewhat stronger in the women not taking hormones, but the effect of nonfasting status was similar to that seen in the entire cohort. A statistically significant interaction was seen between fasting/nonfasting status and apolipoprotein B-100/A-1 for incident CVD in non hormone users (P for interaction 0.001), and a borderline significant interaction was seen between LDL cholesterol and CVD in hormone users (P for interaction 0.06). Next, to determine the effect of time since the last meal on concentrations of lipids and apolipoproteins, we plotted the median, 25th percentile, and 75th percentile postprandial values by 2-hour intervals (Figure 1). Except for triglycerides, there were no substantial changes in the distributions of lipid and apolipoprotein concentrations as a function of time since the last meal. The highest levels of triglycerides were noted 4 to 5 hours postprandially, which was seen in women with HDL cholesterol 50 or 50 mg/dl. Figure 2 shows the adjusted HRs (95% CIs) for CVD of each of the lipid and apolipoprotein concentrations (per 1-SD increments) depending on the time since the last meal before the blood draw. For total cholesterol, LDL cholesterol, and non-hdl cholesterol, significant associations with CVD were noted only after at least 10 hours postprandially. By contrast, the strongest associations for the other lipids and apolipoproteins were noted 6 to 8 hours postprandially. Discussion In this prospective study of initially healthy women, the concentrations of lipids and apolipoproteins differed minimally when measurements were performed on nonfasting compared with fasting blood, except for triglycerides, which were higher when nonfasting. However, the associations with CVD were stronger for fasting compared with nonfasting measurements of total cholesterol, LDL cholesterol, apolipoprotein B-100, non-hdl cholesterol, and the apolipoprotein B-100/A-1 ratio. By contrast, the associations with CVD were similar for fasting and nonfasting HDL cholesterol, apolipoprotein A-1, and the total/hdl cholesterol ratio and stronger for nonfasting triglycerides. These observations suggest that nonfasting blood draws may be highly effective and practical when limited to HDL cholesterol, total/hdl cholesterol ratio, and triglycerides. However, these data also suggest that a fasting sample is preferred if
7 Mora et al Fasting vs Nonfasting Lipids and Incident CVD 7 risk assessment is based on total cholesterol, LDL cholesterol, or non-hdl cholesterol. Prior studies have found lower concentrations of LDL cholesterol postprandially and higher triglycerides, with a similar magnitude of difference in our study compared with prior studies that used a typical non high-fat meal. 6,15,16 Our finding that there was no significant difference between fasting and nonfasting measurements of HDL cholesterol and apolipoprotein A-1 is also consistent with other studies. 17,18 However, to our knowledge, this is the first study that prospectively compares the association of a comprehensive panel of lipids and apolipoproteins with CVD depending on the time to last meal. Although prior studies have evaluated the effect of food intake on lipid and apolipoprotein concentrations, 6,16,17,19 22 the influence of postprandial time on the predictive value of lipids and apolipoproteins, other than triglycerides, is scarce. In a prior case-control report examining 683 postmenopausal healthy women that included some who were nonfasting, the results were not analyzed according to fasting status except for triglycerides, which showed similar prediction in the fasting or nonfasting state. 23 The Apolipoprotein-related MOrtality RISk (AMORIS) study included a large proportion of women, with a third of participants who were nonfasting, but associations of lipids and apolipoproteins with fatal myocardial infarction were not Figure 2 (Continued). reported according to fasting status. 24 Other prospective studies that included a large number of nonfasting participants had data only on men and did not have comparisons with fasting lipids Although differences between fasting and nonfasting concentrations of lipids and apolipoproteins, except for triglycerides, were small and clinically insignificant in our study, the strength of the association of various lipids and apolipoproteins with CVD differed by fasting/ nonfasting status. Total cholesterol and LDL cholesterol showed the most marked differences in their predictive value, although different associations were also found for apolipoprotein B-100, non-hdl cholesterol, and the apolipoprotein B-100/A-1 ratio, all of which were stronger in the fasting state. This finding suggests that performing a nonfasting measurement of total cholesterol or non-hdl cholesterol, which is currently believed to be acceptable, may need to be interpreted with caution. As suggested by Figure 2, even stronger associations may be observed within 6 to 8 hours postprandially for lipids and apolipoproteins that represent part of the atherogenic dyslipidemia of the metabolic syndrome, such as HDL cholesterol and triglycerides, whereas longer durations of fasting ( 10 to 12 hours) may be required for total cholesterol and LDL cholesterol. The underlying biological explanation for this is unclear but may relate to the time course of postprandial triglyceride metabolism because 4 to 8 hours is the time of
8 8 Circulation September 2, 2008 Sources of Funding The Women s Health Study is supported by grants HL and CA from the National Heart, Lung, and Blood Institute and the National Cancer Institute and by grants from the Donald W. Reynolds Foundation, Leducq Foundation, and Doris Duke Charitable Foundation, with additional support from an Investigator- Initiated Studies Program from Merck. Dr Mora is supported by grants from the American Heart Association ( N), Sandra Daugherty Foundation, and Lerner Research Young Investigator Award. The funding agencies played no role in the design, conduct, data management, analysis, or manuscript preparation related to this manuscript. None. Disclosures Figure 2 (Continued). peak triglycerides, and by 8 hours, triglyceride concentrations have returned to fasting concentrations in most individuals. 28 The present study has several limitations. Time to last meal was self-reported, and we did not have both fasting and nonfasting measurements in the same individuals. Lipid measurements were only available once at baseline, and results could not be corrected for potential regression dilution bias. We only had data on women, although no substantial differences were noted in women who were or were not taking hormones. Our study included healthcare professionals who were mostly white, apparently healthy, and recruited from a variety of geographic locations across the United States; thus, it is unclear if our results would be applicable to other ethnic populations or men. Our statistical power was less in nonfasting than in fasting women. Finally, this was a primary prevention population, and further studies are needed before the data can be extended to secondary prevention populations that are frequently treated with lipid-lowering medications. Strengths of the present study include the large number of healthy women participants with comprehensive measurements of a panel of lipids and apolipoproteins, including the direct measurement of standard lipids. Additionally, detailed information on cardiovascular risk factors was available, allowing for the control for potential confounding by these factors, such as the time of day of blood draw and hormone use. Finally, previous studies have not examined the influence of fasting status on the predictive ability of various lipids and lipoproteins, other than triglycerides, all of which was possible in this study because of the large number of participants in subgroups divided by time since the last meal. In summary, this study demonstrates that HDL cholesterol, triglycerides, total/hdl cholesterol ratio, and apolipoprotein A-1 predict CVD when measured nonfasting. By contrast, total, LDL, and non-hdl cholesterol, in addition to apolipoprotein B-100 and B-100/A-1 ratio, may provide less useful CVD risk information when measured nonfasting, despite small changes in their concentrations. Guidelines for lipid screening may need to consider these differences. References 1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2003;171: Bachorik PS, Ross JW; National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem. 1995;41: Rifai N, Dufour DR, Cooper GR. Preanalytical variation in lipid, lipoprotein, and apolipoprotein testing. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. 2nd ed. Washington, DC: AACC Press; 2000: Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med. 2000;15: Wilder LB, Bachorik PS, Finney CA, Moy TF, Becker DM. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol. Am J Med. 1995;99: Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med. 2003;163: Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298: Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298: O Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100: Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352: Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women s Health Study: a randomized controlled trial. JAMA. 2005;294: Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women s Health Study: a randomized controlled trial. JAMA. 2005;294: Hainline A, Karon J, Lippel K. Manual of Laboratory Operations: Lipid Research Clinics Program and Lipid and Lipoprotein Analysis. 2nd ed. Bethesda, Md: Department of Health and Human Services; Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, Pauli AM, Borel P, Latge C, Lairon D. Effects of graded amounts (0 50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr. 1998;67:31 38.
9 Mora et al Fasting vs Nonfasting Lipids and Incident CVD Dubois C, Armand M, Mekki N, Portugal H, Pauli AM, Bernard PM, Lafont H, Lairon D. Effects of increasing amounts of dietary cholesterol on postprandial lipemia and lipoproteins in human subjects. J Lipid Res. 1994;35: Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem. 1988;34: Rifai N, Merrill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem. 1990;27: Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res. 1988;29: Dubois C, Armand M, Azais-Braesco V, Portugal H, Pauli AM, Bernard PM, Latge C, Lafont H, Borel P, Lairon D. Effects of moderate amounts of emulsified dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr. 1994;60: Schaefer EJ, Audelin MC, McNamara JR, Shah PK, Tayler T, Daly JA, Augustin JL, Seman LJ, Rubenstein JJ. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol. 2001;88: Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JA, Seman LJ, Ferrari A, Rubenstein JJ. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol. 2002;90: Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004;110: Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358: Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ. 1989;298: Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22: Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276: Campos H, Khoo C, Sacks FM. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans. Atherosclerosis. 2005;181: CLINICAL PERSPECTIVE Current guidelines recommend measurement of a fasting lipid profile for cardiovascular risk assessment. Recent studies suggest that nonfasting triglycerides may better or similarly predict cardiovascular disease (CVD) events than fasting levels. Measurement of nonfasting lipids may have many practical advantages for clinical practice, but it is unknown whether nonfasting status alters the association of nontriglyceride lipids and apolipoproteins with CVD. Using prospectively collected data from the Women s Health Study with healthy women ( fasting; 6347 nonfasting) followed over an 11-year period, we examined the association of CVD with baseline lipids and apolipoproteins according to time from last meal. We found that the concentrations of lipids and apolipoproteins differed minimally when measurements were performed on nonfasting ( 8 hours from last meal) compared with fasting blood ( 8 hours from last meal), except for triglycerides, which were higher when nonfasting. However, the associations with CVD were stronger for fasting compared with nonfasting measurements of total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B-100, non high-density lipoprotein (non-hdl) cholesterol, and the apolipoprotein B-100/A-1 ratio. By contrast, the associations with CVD were similar for fasting and nonfasting HDL cholesterol, apolipoprotein A-1, and the total/hdl cholesterol ratio and stronger for nonfasting triglycerides. These observations suggest that nonfasting blood draws may be highly effective and practical when limited to HDL cholesterol, total/hdl cholesterol ratio, triglycerides, and apolipoprotein A-1. However, these data also suggest that a fasting sample is preferred if risk assessment is based on total cholesterol, low-density lipoprotein cholesterol, non-hdl cholesterol, apolipoprotein B-100, and apolipoprotein B-100/ A-1 ratio.
10 Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events Samia Mora, Nader Rifai, Julie E. Buring and Paul M Ridker Circulation. published online August 18, 2008; Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX Copyright 2008 American Heart Association, Inc. All rights reserved. Print ISSN: Online ISSN: The online version of this article, along with updated information and services, is located on the World Wide Web at: Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document. Reprints: Information about reprints can be found online at: Subscriptions: Information about subscribing to Circulation is online at:
The Second Report of the Expert Panel on Detection,
Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare
More informationHuman consumption of food usually is evenly distributed. Epidemiology
Epidemiology Fasting and Nonfasting Lipid Levels Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction Anne Langsted, BMSc; Jacob J. Freiberg, MD;
More informationJAMA. 2005;294:
ORIGINAL CONTRIBUTION Non HDL Cholesterol, Apolipoproteins A-I and B 100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women Paul M Ridker, MD Nader Rifai,
More informationLipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women
Diabetes Publish Ahead of Print, published online February 25, 2010 Lipoprotein Particle Size and Concentration by Nuclear Magnetic Resonance and Incident Type 2 Diabetes in Women Samia Mora, MD, MHS,
More informationNon-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
Diabetologia (2011) 54:73 77 DOI 10.1007/s00125-010-1945-z SHORT COMMUNICATION Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus S. van Dieren & U. Nöthlings & Y.
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationC-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS
COMPARISON OF C-REACTIVE PROTEIN AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS IN THE PREDICTION OF FIRST CARDIOVASCULAR EVENTS PAUL M. RIDKER, M.D., NADER RIFAI, PH.D., LYNDA ROSE, M.S., JULIE E. BURING,
More informationDietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women
07/14/2010 Dietary Fatty Acids and the Risk of Hypertension in Middle-Aged and Older Women First Author: Wang Short Title: Dietary Fatty Acids and Hypertension Risk in Women Lu Wang, MD, PhD, 1 JoAnn E.
More informationARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients
ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationThe apolipoprotein story
Atherosclerosis Supplements 7 (2006) 23 27 The apolipoprotein story Frank M. Sacks a,b, a Department of Nutrition, Harvard School of Public Health, Boston, MA, USA b Department of Medicine, Harvard Medical
More informationNonfasting LDL-C as a Predictor of Cardiovascular Event Risk
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-13-2016 Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Richard
More informationEpidemiological studies indicate that a parental or family
Maternal and Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women Howard D. Sesso, ScD, MPH; I-Min Lee, MBBS, ScD; J. Michael Gaziano, MD, MPH; Kathryn M. Rexrode,
More informationFibrinogen is a circulating glycoprotein that has long been. Epidemiology
Epidemiology Additive Value of Immunoassay-Measured Fibrinogen and High-Sensitivity C-Reactive Protein Levels for Predicting Incident Cardiovascular Events Samia Mora, MD, MHS; Nader Rifai, PhD; Julie
More informationApolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.13 Apolipoprotein B in the Risk Assessment and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationPatients with the metabolic syndrome are at increased risk
Clinical Investigation and Reports C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events An 8-Year Follow-Up of 14 719 Initially Healthy American Women Paul M Ridker, MD;
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More information. Non HDL-c : Downloaded from ijdld.tums.ac.ir at 18:05 IRDT on Friday March 22nd Non HDL LDL. . LDL Non HDL-c
208-23 (2 ) 0 389 -. Non HDL * Downloaded from ijdld.tums.ac.ir at 8:05 IRDT on Friday March 22nd 209 Non HDL : LDL.. 5 3277 :.. odds ratio Chi-Square %3/9 Non HDL-C %2 LDL-C. %3 : Non-HDL-C LDL-C. (CI
More informationREAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationInflammation plays a major role in atherosclerosis, 1 and
Soluble P-Selectin and the Risk of Future Cardiovascular Events Paul M. Ridker, MD; Julie E. Buring, ScD; Nader Rifai, PhD Background P-selectin, a cell-surface adhesion molecule involved in leukocyte
More informationRe-assessing the role of non-fasting lipids; a change in perspective
Editorial Page 1 of 5 Re-assessing the role of non-fasting lipids; a change in perspective Zareen Farukhi 1,2, Samia Mora 1,2 1 Center for Lipid Metabolomics, Division of Preventive Medicine, 2 Department
More informationImproving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B The Copenhagen City Heart Study Marianne Benn, Børge G. Nordestgaard, Gorm Boje Jensen, Anne Tybjærg-Hansen
More informationJournal of the American College of Cardiology Vol. 59, No. 17, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 59, No. 17, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.035
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationHigh-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease. Original Policy Date
MP 2.04.17 High-Density Lipoprotein Subclass Testing in the Diagnosis and Management of Cardiovascular Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationThe inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema
The inhibition of CETP: From simply raising HDL-c to promoting cholesterol efflux and lowering of atherogenic lipoproteins Prof Dr J Wouter Jukema Dept Cardiology, Leiden University Medical Center, Leiden,
More informationJoint role of non-hdl cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes
Diabetologia (2004) 47:2129 2136 DOI 10.1007/s00125-004-1593-2 Joint role of non-hdl cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes
More informationModerate alcohol consumption is associated with decreased
Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease
ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple
More informationAtherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol
Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol Patrick R. Lawler, MD, MPH; Akintunde O. Akinkuolie, MBBS,
More informationNon-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes RUI JIANG, MD, DRPH 1,2 MATTHIAS
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationOf the 1.5 million heart attacks
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke Paul M Ridker, MD, MPH Of the 1.5 million heart attacks and 600 000 strokes
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationElevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes FRANK B. HU, MD 1,2,3 MEIR J. STAMPFER,
More informationSmall dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study
Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori
More informationCLINICAL RESEARCH STUDY
CLINICAL RESEARCH STUDY Determining Triglyceride Reductions Needed for Clinical Impact in Severe Hypertriglyceridemia Jennifer B. Christian, PharmD, MPH, PhD, a Bhakti Arondekar, BPharm, MBA, PhD, b Erin
More informationEffect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial
European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo
More informationSaturated fat- how long can you go/how low should you go?
Saturated fat- how long can you go/how low should you go? Peter Clifton Baker IDI Heart and Diabetes Institute Page 1: Baker IDI Page 2: Baker IDI Page 3: Baker IDI FIGURE 1. Predicted changes ({Delta})
More informationAtherosclerosis 213 (2010) Contents lists available at ScienceDirect. Atherosclerosis
Atherosclerosis 213 (2010) 299 305 Contents lists available at ScienceDirect Atherosclerosis journal homepage: www.elsevier.com/locate/atherosclerosis Inflammatory markers, lipoprotein components and risk
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Measurement of Small Low Density Lipoprotein Particles sad EFFECTIVE DATE: 02 16 2010 POLICY LAST UPDATED: 10 15 2013 OVERVIEW Lipoprotein-associated phospholipase A2 (Lp-PLA2),
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationMeasures of Obesity and Cardiovascular Risk Among Men and Women
Journal of the American College of Cardiology Vol. 52, No. 8, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.03.066
More informationjournal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
More informationJournal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.
Journal of the American College of Cardiology Vol. 54, No. 25, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.005
More informationThe Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population
The Association of Apolipoprotein B and Low Density Lipoprotein with Cardiovascular Risk Factors in the Thai Population Rungroj Krittayaphong MD*, Chunhakasem Chotinaiwatarakul MD**, Charuwan Kangkagate
More informationThe New England Journal of Medicine C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN PAUL M. RIDKER, M.D., CHARLES H. HENNEKENS, M.D., JULIE E. BURING, SC.D., AND NADER RIFAI, PH.D.
More informationEffects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease.
Michael Garshick, MD PGY-1 Columbia University Medical Center Effects of a dietary intervention to reduce saturated fat on markers of inflammation and cardiovascular disease. Study Purpose and Rationale:
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationStudy of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease
Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,
More informationKatsuyuki Nakajima, PhD. Member of JCCLS International Committee
Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham
More informationFolate, vitamin B 6, and vitamin B 12 are cofactors in
Research Letters Dietary Folate and Vitamin B 6 and B 12 Intake in Relation to Mortality From Cardiovascular Diseases Japan Collaborative Cohort Study Renzhe Cui, MD; Hiroyasu Iso, MD; Chigusa Date, MD;
More informationThe Impact of Diabetes Mellitus and Prior Myocardial Infarction on Mortality From All Causes and From Coronary Heart Disease in Men
Journal of the American College of Cardiology Vol. 40, No. 5, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02044-2
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationpatient-oriented and epidemiological research
patient-oriented and epidemiological research Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese Kuo-Liong Chien, 1, *,, Hsiu-Ching Hsu, Ta-Chen
More informationIt is currently estimated that diabetes prevalence by
clinical Study The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India Hetal Pandya*, JD Lakhani**, J Dadhania, A Trivedi Abstract Only proper
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationTHE C-REACTIVE PROTEIN IS A
ORIGINAL CONTRIBUTION C-Reactive Protein and the Risk of Developing Hypertension Howard D. Sesso, ScD, MPH Julie E. Buring, ScD Nader Rifai, PhD Gavin J. Blake, MD, MPH J. Michael Gaziano, MD, MPH Paul
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationTriglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationORIGINAL INVESTIGATION. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women
The Impact of Mellitus on Mortality From All Causes and Coronary Heart Disease in Women 20 Years of Follow-up ORIGINAL INVESTIGATION Frank B. Hu, MD; Meir J. Stampfer, MD; Caren G. Solomon, MD; Simin Liu,
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationORIGINAL INVESTIGATION. Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease
ORIGINAL INVESTIGATION Alcohol Consumption and Mortality in Men With Preexisting Cerebrovascular Disease Vicki A. Jackson, MD; Howard D. Sesso, ScD; Julie E. Buring, ScD; J. Michael Gaziano, MD Background:
More informationAlthough the association between blood pressure and
Two-Year Changes in Blood Pressure and Subsequent Risk of Cardiovascular Disease in Men Howard D. Sesso, ScD, MPH; Meir J. Stampfer, MD, DrPH; Bernard Rosner, PhD; J. Michael Gaziano, MD, MPH; Charles
More informationLow density lipoprotein cholesterol (LDL-C) is the traditional
Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-crp as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes Results From PROVE
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationC-Reactive Protein Levels and Outcomes after Statin Therapy
The new england journal of medicine original article C-Reactive Protein Levels and Outcomes after Statin Therapy Paul M Ridker, M.D., Christopher P. Cannon, M.D., David Morrow, M.D., Nader Rifai, Ph.D.,
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationThe recently released American College of Cardiology
Data Report Atherosclerotic Cardiovascular Disease Prevention A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, MD; Colby
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL A Meta-analysis of LDL-C, non-hdl-c, and apob as markers of cardiovascular risk. Slide # Contents 2 Table A1. List of candidate reports 8 Table A2. List of covariates/model adjustments
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationLIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationInfluence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial
JACC Vol. 33, No. 1 January 1999:125 30 125 Influence of Baseline Lipids on Effectiveness of Pravastatin in the CARE Trial MARC A. PFEFFER, MD, PHD, FACC, FRANK M. SACKS, MD, LEMUEL A. MOYÉ, MD, PHD,*
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationStandard lipid tests measure the cholesterol or triglyceride
CONTROVERSIES IN CARDIOVASCULAR MEDICINE Are advanced lipoprotein testing and subfractionation clinically useful? Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical
More information